Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by carduon Sep 16, 2004 11:31am

302 Views

Post# 7927922

RE: RAS activated

refer to the following subway map of cancer pathways to see how an activated RAS pathway is involved in the growth of cancer. https://www.nature.com/nrc/journal/v2/n5/weinberg_poster/ Ras proteins work as molecular 'on/off' switches that can change the way cells grow, and interact with other cells. Mutated forms of Ras that are locked in the 'on' position. You will notice that RAS controls more of the proliferative signals and genetic changes that confer upon an incipient neoplastic cell the properties of unlimited, self-sufficient growth involved in metastatic cancer.

Bullboard Posts

StockTalk | Gold Report: A week of mineralized expansion